Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665
Burton Eisenberg(Dartmouth College), Margaret von Mehren(Fox Chase Cancer Center), Charles D. Blanke(Oregon Health & Science University), George D. Demetri(Dana-Farber Cancer Institute), Jonathan Harris(American College of Radiology), Michael C. Heinrich(Oregon Health & Science University), John M. Kane(Roswell Park Comprehensive Cancer Center), Scott H. Okuno(Mayo Clinic), John P. Hoffman(Fox Chase Cancer Center), James C. Watson(University of Nebraska Medical Center)
Cited by 419
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
|Journal of the National Comprehensive Cancer Network|2010|1.2k